Frontlight ResearchEarly access
CompletedNo phase
Novel Exhaled Breath Aerosol Collection Devices in Patients With Lower Respiratory Tract Infection - a Performance and Acceptability Study
Key facts
- Who runs it
- Avelo AG
- Where
- Switzerland1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 23 people enrolled
- Started
- 13 Nov 2024
- Ended
- 21 May 2025
- Type of study
- Observational
- Treatments tested
- Sputum collection for molecular analysis
- Breath and cough collection for molecular analysis
- Record updated
- 8 August 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Able to understand the scope of the study and provide written informed consent
- Age >18 years
- Speaking German or English
- Health status (assessed by study personnel at local site) well enough to use the breath collection devices
- Willing to provide all three study samples (sputum and two breath samples) required for the study
- Clinical diagnosis of a lower respiratory tract infection (LRTI) defined as:; (i) New infiltrate (chest X-ray, ultrasound, or CT scan), and (ii) at least one clinical symptom suggestive of LRTI (fever ≥38°C, chills, new or worsening cough, new or worsening sputum production, new or worsening dyspnea, tachypnoea, chest pain)
Who cannot take part
- Hospitalization within the last 14 days prior to admission
- Patients for whom the collection of all three study specimens within 48 hours of initiating antibiotic treatment is not feasible
- Patients with known cystic fibrosis or bronchiectasis
- Critically ill patients at the discretion of the investigator
- Patients on oxygen supplementation with a face mask, high-flow-oxygen, non-invasive or mechanical ventilation; oxygen supplementation via nasal cannula will be permitted
- Patients with proven acute pulmonary embolism
- Patients with best supportive care
- Patients with severe hypoxemia (SpO2 <88%) despite oxygen supplementation
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study will assess the performance of two novel breath collection devices and their subsequent detection of respiratory pathogens compared to sputum samples in patients with lower respiratory tract infections.
Treatments tested
- Sputum collection for molecular analysis
- Breath and cough collection for molecular analysis
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Novel Exhaled Breath Aerosol Collection Devices in Patients With Lower Respiratory Tract Infection - a Performance and Acceptability Study (Acronym: AeroCAP)
- Record updated
- 8 August 2025